REMEDY is part of a portfolio of projects
funded under the Engineered Living
Materials Pathfinder Challenge by the European Innovation Council and started
on November 2022. With this Pathfinder ELMs Challenge the EIC seeks to seize
the opportunity to position
strategically Europe at the forefront of the ELMs field. This Pathfinder
Challenge aims to overcome the technological challenges to harness the engineering
potential of nature for materials’ production. The specific objectives of Pathfinder ELMs Challenge are to
support the development of new technologies and platforms enabling the
controlled production of made-on-demand living materials with multiple
predictable dynamic functionalities, shapes and scales; and to build a
community of Researchers and innovators
in ELMs.
ELMs projects funded from the EIC Open calls actively
contribute to the Portfolio activities with the aim to advance the scientific
and technological development of ELMs and promote its dissemination across
Europe, increase the visibility of the ELMs community internationally by
sharing knowledge and building partnerships, engage with regulatory bodies to
address ELMs portfolio needs, address ethical, legal and social aspects through
early engagement with policymakers and the public, and to assess and address
the need for standardization in the ELMs portfolio, identify barriers to the
adoption and commercialization of ELMs and engage with stakeholders, guided by
responsible research and innovation methods.”
Discover how each project in the EIC ELMs portfolio aims to develop cheaper and more sustainable materials using living materials in a new video by Horizon Results Booster (a free service of the European Commision). The projects are pushing the technological boundaries in developing ELMs working together to overcome challenges and position Europe’s ELMs at the forefront of scientific and technological developments in the field.
Discover why the European Innovation Council (EIC) is prioritizing portfolio management to boost Europe’s technological autonomy. Learn which are the projects in the portfolio working on common research interests and challenges to increase the chances of success.
Discover the objectives and the activities to reach those objectives of the EIC ELMs Portfolio in advancing living materials technology and shaping Europe’s leadership in this field. This strategic plan is a living document. Future updates can be found in the yearly progress reports of the EIC ELMs Portfolio.
On February 6, 2025, we were thrilled to see several pioneering projects from the EIC ELMs Portfolio—PRISM-LT, -LoopOfFun-ELMs, NextSkins, Bio-HhOST, BioRobot-MiniHeart, ISOS Project EU, Bioaction EU, REMEDY —participate in the EIC-EMA Workshop on the Regulatory Framework of Engineered Living Materials (ELMs).
Co-organized by the European Innovation Council (EIC) and the European Medicines Agency (EMA), this workshop served as a vibrant exchange platform for ELM researchers to explore regulatory challenges. These innovative materials are set to transform medicine and biotechnology, marking a critical milestone for ELMs in Europe.
With keynotes from Barbara Gerratana (EIC), Orsolya Symmons (EIC), and @Costantinos Ziogas (EMA), the event ignited insightful discussions. The panel, co-moderated by Falk Ehmann (EMA) and Laura Martinelli (PRISM-LT, INsociety), delved into essential topics like:
- ELM product classification and approval pathways
- Safety and compliance requirements
- Clinical trials for bioprinted and engineered tissues
- EMA’s guidance on ATMPs
This interactive session encouraged a plethora of questions and underscored the imperative for ongoing regulatory dialogue as ELM technologies continue to evolve. The workshop provided valuable insights into the changing regulatory landscape, highlighting the necessity for continuous collaboration among innovators, regulatory bodies, and industry stakeholders.
Discover the progress made by the EIC ELMs Portfolio in advancing living materials technology and shaping Europe’s leadership in this field. This report highlights key achievements since the 2023 strategic plan and outlines the objectives for the third year of the Portfolio.
Original link of the dokument.
Coordinator: CNR (IT)
Project partners
: 7
Key-words: bio-hydrogels, bactoinfection, liposome, phages, hard tissue regeneration, processing technologies
BIOACTION aims at developing a new methodology in implant technology based on functionalized bio-hydrogels that will convert the negative occurrence of biofilm-associated infections, the primary cause of implant infections and failure, into a positive resource. The main goal of BIOACTION is to transform implant-associated bacteria for the programmable production of specific proteins for in vivo cell recruitment and tissue regeneration, exploiting gene sequences loaded on engineered liposomes and phages, bound to hydrogel scaffolds. BIOACTION will develop new biomimetic substrates that can transform biofilm into extracellular matrix for the regeneration of target tissues. It will establish a high versatile technology to be used as injectable materials and implant coatings for periodontal and peri-implant infection treatments. The proposed approach will be validated in two clinically relevant animal models: dental implant and permanent transcutaneous bone. BIOACTION, would radically advance the future of infection treatment by revolutionizing the classical approaches leading to the improvement of state of care, health outcomes and to achieve huge socio-economic benefits. The project is strongly interdisciplinary in nature involving expertise biomaterials, synthetic biology, phage and liposome technology, medicine.
Coordinator
:
University of Trento, Italy
Project partners
:
7
Key-words
:
synthetic biology, artificial cells, 3D bioprinting, microfluidics, 3D cell culture
Bio-hybrid materials and physiochemical interactions hold great promise for advancing the pharmaceutical and chemical sectors. However, current developments in these technologies are limited, with few functional options available. In this context, the EIC-funded Bio-HhOST project aims to develop a bio-hybrid material composed of living and artificial cells, enabling a wide range of interactions. The incorporation of artificial cells will facilitate the proliferation, function, and differentiation of living cells, while also possessing functional metabolisms capable of revolutionising the sector through chemical interactions. Additionally, the project employs 3D tissue models and simulations to enhance the understanding of the material and its response to diseases, thereby reducing the necessity for animal research.
Coordinator: University of Twente (NL)
Project partners
: 4
Key-words: tissue engineering, biosensing, stem cells, cardiovascular diseases, physiology
Manufacturing our very own hearts is just a heartbeat away, literally. Engineers are joining forces with biologists to make biological heart robots. The EU-funded BioRobot-MiniHeart project is developing a vascularised beating mini-heart. In parallel, the team is designing a self-propulsion swimming bio-robot created by assembling human cardiac cells into 3D tissue structures; using sacrificial moulding and high-resolution 3D bioprinting. The mini-heart and the bio-robot will provide scientists with a more realistic human cardiac model in vitro and an appropriate tool to assess cardiotoxicants’ presence in the environment. We expect this innovation to help speed up the development of heart disease cures.
Coordinator: Royal Danish Academy – Architecture, Design,
Conservation (DK)
Project partners
: 6
Key-words: bacteriology, synthetic biology, mycology
Engineered living materials (ELMs) are
composed of living cells endowed with unique properties and functions. ELMs
have received significant attention in materials sciences due to their
tuneability and potential for sustainable production. Funded by the European
Innovation Council, the Fungateria project aims to generate an innovative
portfolio of ELMs that combine fungi with bacteria.
Growing the vegetative part of the
mushroom—the mycelium—on different organic substrates is the most common way of
producing fungi-based materials. The project will combine the mycelium with
bacteria that serve as a chassis for sensor-containing genetic circuits. The
resultant ELMs will exhibit advanced functionalities and inducible degradation
when no longer needed.
Coordinator: SILK BIOMED S.L.
Project partners
: 6
Key-words: GEB, ELM, silk fibroin, micro bioreactor, chronic diseases, aged-related macular degeneration
ISOS is pioneering the development of a groundbreaking biomedical solution: a bioreactor housing genetically engineered probiotic bacteria (GEB) within biomaterials. This innovation is aimed at chronic diseases requiring extended treatments. Encapsulated GEB populations synthesize therapeutic molecules in response to patient-specific signals such as inflammation or reactive oxygen species. Designed to maintain dynamic equilibrium and ensure GEB survival within the pathological environment, ISOS offers personalized treatment through in-silico tools and synthetic biology. As a Proof-of-Concept, ISOS plans to deploy an implantable GEB-based bioreactor for treating wet age-related macular degeneration (wAMD). This advancement aims to replace frequent Anti-VEGF injections with a single bioreactor, enhancing therapeutic efficacy and minimizing side effects. ISOS pioneers a new therapeutic approach using recombinant probiotic libraries, promising precise local drug production and efficient delivery tied to dynamic pathological cues.
Coordinator: Albert-Ludwigs-Universitaet
Freiburg (ALU-FR) (DE) until 30.06.2023. From 01.07.2023 Leibniz-Institut fuer
neue Materialien gemeinnutzige GmbH (INM) (DE) is the coordinator because of
the switch of the PI and his team from ALU-FR to INM
Project partners
: 5
Key-words: mycology, electrical engineering, sensors
Fungi comprise approximately 100 000 described species to date. The real total is estimated to be in the millions. They are amazing factories, producing numerous bioactive metabolites of therapeutic interest. The EU-funded LoopOfFun project has recognised their potential in yet another innovative area – as part of engineered living materials (ELMs), with open- and closed-loop control of mechanical and structural properties. The project will identify fungi gifted with superior abilities for materials synthesis and harness them for synthetic biology-based programming. The programming will be accomplished via a novel automatic robotised platform to develop the fungi into ELMs based on iterative design-build-test-learn cycles. The outcomes will then support the rational design of such materials.
Coordinator: Delft University of Technology (NL)
Project partners
: 3
Key-words: bacteriology, synthetic biology, mycology
Compared to conventional materials,
biomaterials in living organisms possess specific architecture and
organisation: and often exhibit multiple functions. Εngineered living materials
(ELMs) have emerged at the junction of synthetic biology and material science
to produce materials with improved functionality because of the living
organisms within them.
Funded by the European Innovation
Council, the NextSkins project is inspired by the structure and function of the
many layers of skin. Researchers will mimic the specialised skin arrangement to
make two engineered living materials: one with a therapeutic role to treat skin
diseases and one with a purpose to be used as a protective garment in sports.
Coordinator:
IN society (IT)
Project partners
: 6
Key-words: bacteriology, stem cells, bioprinting
The EU-funded PRISM-LT project will use a hybrid living materials concept to create a flexible platform for living tissue manufacturing. The innovative bio-ink will contain stem cells integrated into a supporting matrix with engineered helper bacteria or yeast cells. The bioprinting process will produce a 3D patterned structure where stem cells could be induced to differentiate into different lineages. The directed stimulation of differentiating stem cells will force them to produce lineage-specific metabolites for sensing by the designer helper cells. The helper cells within the platform will then enhance localised lineage commitment to sustain differentiation stability. The project aims to implement this strategy for the development of two symbiotic materials designed for biomedical and food applications, respectively.
Coordinator:
InnoRenew CoE (SI)
Project partners
: 6
Key-words: microbiology, architecture, biofabrication,
microbiome
The REMEDY project pioneers the archibiome tattoo - a living, bespoke layer for buildings that enhances both, aesthetics and functionality. By integrating advances in microbiology, synthetic biology, and materials science, REMEDY develops engineered living materials and specialized biofabrication process for personalized architectural design. At the core of REMEDY’s approach are tailored microbial consortia formulated into innovative microbial inks that function like probiotic skincare. These living consortia establish a resilient microbiome on building surfaces, providing pathogen protection, supporting carbon sequestration, producing oxygen, and enabling bioremediation. Funded by the European Innovation Council, REMEDY brings metabolic thinking into sustainable design, advances probiotic architecture, and drives a microbial revolution to reshape the perception of microorganisms in the built environment.
Coordinator:
Oslo University Hospital (NO)
Project partners
: 7
Key-words: artificial intelligence, developmental biology,
stem cells, physiology
The lack of realistic in vitro organ
models that faithfully represent in vivo physiological processes is a major
obstacle affecting the biological and medical sciences. The current gold
standard is animal experimentation, but it is increasingly evident that these
models mostly fail to recapitulate human physiology. Moreover, animal
experiments are controversial, and it is a common goal in the scientific
community to minimise the use of animals to a strictly necessary minimum.
The emergence of stem cell-engineered
organ models called organoids represents the only viable alternative to animal
research. However, current organoid technology is yet to produce the larger
physiologically relevant organ models that the medical sciences need.
Specifically, current organoids are too small, not vascularised and lack the
3-dimensional organisation found in vivo.
In this interdisciplinary project, we aim
to challenge all these limitations using the recently developed gastruloid
technology guided by cutting-edge bioengineering and artificial intelligence.
Gastruloids are formed by initiating the
very early developmental processes and develop along a highly coordinated
three-axial process that closely resembles mammalian embryogenesis. They can
establish several organ precursors simultaneously, thus constituting relevant
improvements over conventional single-tissue organoids.
To harvest the potential of gastruloid
technology, we will first implement extensive sequencing and imaging
experiments to optimise the developmental trajectory of gastruloids for organ
inductions. We will then build these datasets into a multimodal data matrix to
identify gastruloid candidates for cardiovascular and foregut development.
Candidates with substantial vasculogenesis will be chosen for later
vascularisation by anastomose with endothelial cells.”
This site was created with the Nicepage